title: Dose-dependent effects of buspirone on behavior and cerebral glucose metabolism in rats.
abstract: In this study we compared the effects of the anxiolytic buspirone on behavior and regional cerebral metabolic rates for glucose (rCMRglc) with those of the reference serotonin (5-HT)1A agonist 8-hydroxy-2(di-N-propylamino)tetralin (DPAT). Behavioral effects were assessed by scoring the 5-HT syndrome. rCMRglc was measured in 56 brain regions by using the quantitative autoradiographic [14C]2-deoxyglucose technique, at 10 min after i.p. injection of DPAT (1 mg/kg) or buspirone (0.4, 4 and 40 mg/kg) in awake male Fischer-344 rats. Whereas DPAT produced an intense 5-HT syndrome, buspirone had no behavioral effect. A low dose (0.4 mg/kg) of buspirone reduced rCMRglc in 18 brain areas (32%), more markedly in limbic areas and raphe nuclei. These were the only rCMRglc effects buspirone had in common with the potent 5-HT1A agonist DPAT and suggest that low dose buspirone activates preferentially 5-HT1A receptors. Hence, this receptor subtype may mediate buspirone functional effects on the limbic system and, given the role of these brain areas in mood control, possibly buspirone therapeutic actions. High doses (4 and 40 mg/kg) of buspirone produced widespread rCMRglc decreases in 46 (82%) and 44 (79%) of the areas studied and increased rCMRglc in one brain area, the lateral habenula, that was not affected by DPAT or a low dose of buspirone. The topographic distribution and direction of rCMRglc changes by high doses of buspirone differ from those produced by the 5-HT1A agonist DPAT. Instead these changes resemble the rCMRglc effects of dopaminergic D2 antagonists like haloperidol and are consistent with some pharmacological and binding properties of buspirone.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Clinica delle Malattie Nervose e Mentali, Padova, Italy.
authors.forename: U
authors.initials: U
authors.lastname: Freo
authors.forename: P
authors.initials: P
authors.lastname: Pietrini
authors.forename: G
authors.initials: G
authors.lastname: Pizzolato
authors.forename: M
authors.initials: M
authors.lastname: Furey-Kurkjian
authors.forename: A
authors.initials: A
authors.lastname: Merico
authors.forename: S
authors.initials: S
authors.lastname: Ruggero
authors.forename: M
authors.initials: M
authors.lastname: Dam
authors.forename: L
authors.initials: L
authors.lastname: Battistin
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002065:Buspirone / Q000494:pharmacology*; D003847:Deoxyglucose; D018491:Dopamine Agonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D008991:Monitoring, Physiologic; D051381:Rats; D011916:Rats, Inbred F344; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013764:Tetrahydronaphthalenes / Q000494:pharmacology
chemical_list: D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D013764:Tetrahydronaphthalenes; D003847:Deoxyglucose; D005947:Glucose; D006220:Haloperidol; C031349:7-hydroxy-2-N,N-dipropylaminotetralin; D002065:Buspirone